This is the authors' abstract. We don't add key points for this paper.
OBJECTIVE: Quantify work loss and costs associated with prescription opioid use disorder (OUD) from the employer perspective. METHODS: Retrospective claims analysis to compare missed work days and associated costs between employees with and without an OUD diagnosis in a 12-month period. RESULTS: Two thousand three hundred eleven matched-pairs of employees were compared. The mean (SD) number of days missed while waiting for disability benefits (0.24 [1.4] vs 0.17 [1.0]; P = 0.035), absenteeism due to disability claims (9.5 [40.9] vs 5.6 [30.0]; P < 0.001), and medical visits (17.8 [18.5] vs 10.0 [12.4]; P < 0.001) was higher for employees with OUD compared with those without, resulting in higher mean (SD) indirect cost estimates of $8193 ($14,694) per employee (OUD) versus $5438 ($13,683) per employee (no OUD) (P < 0.001). CONCLUSIONS: Prescription OUD is associated with significant work loss and may pose considerable economic burden on employers.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
White et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: